share_log

Grant of Restricted Stock Units and Warrants to Employees in Genmab

Grant of Restricted Stock Units and Warrants to Employees in Genmab

向Genmab员工授予限制性股票单位和认股权证
GlobeNewswire ·  2022/09/20 15:25

Company Announcement

公司公告

COPENHAGEN, Denmark; September 20, 2022 Genmab A/S (Nasdaq: GMAB) announced today that the board decided to grant 19,782 restricted stock units and 19,789 warrants to employees of the Company and the Company's subsidiaries. 

哥本哈根、丹麦;9月20日, 2022Genmab A/S (纳斯达克: GMAB) 今天宣布,董事会决定授予19,782限制性股票单位和 19,789向本公司及本公司附属公司的员工发出认股权证。

Each restricted stock unit is awarded cost-free and provides the owner with a right and obligation to receive one share in Genmab A/S of nominally DKK 1. The fair value of each restricted stock unit is equal to the closing market price on the date of grant of one Genmab A/S share, DKK 2,585. 

每个限制性股票单位是免费授予的,并向所有者提供了获得名义上为1丹麦克朗的Genmab A/S的一股的权利和义务。每个受限股票单位的公允价值等于授予一股Genmab A/S股票之日的收盘价2,585丹麦克朗。

The restricted stock units will vest on the first banking day of the month following a period of three years from the date of grant. Furthermore, the restricted stock units are subject to vesting conditions set out in the restricted stock unit program adopted by the board of directors. Information concerning Genmab's restricted stock unit program can be found on under Investors > Governance > Compensation > Restricted stock units.  

限制性股票单位将在授予之日起三年后的下一个月的第一个银行日授予。此外,限制性股票单位受董事会通过的限制性股票单位方案中规定的归属条件的约束。有关Genmab限制性股票单位计划的信息,可以在投资者>治理>薪酬>限制性股票单位下找到。 

The exercise price for each warrant is DKK 2,585. Each warrant is awarded cost-free and entitles the owner to subscribe one share of nominally DKK 1 subject to payment of the exercise price. By application of the Black-Scholes formula, the fair value of each warrant can be calculated as DKK 861.25. 
The warrants vest three years after the grant date, and all warrants expire at the seventh anniversary of the grant date. The new warrants have been granted on the terms and conditions set out in the warrant program adopted by the board of directors on February 23, 2021. Information concerning Genmab's warrant schemes can be found on under Investors > Governance > Compensation > Warrants. 

每份认股权证的行使价为2585丹麦克朗。每份认股权证是免费授予的,并使所有者有权在支付行使价格的情况下认购名义上为1丹麦克朗的一股。通过应用布莱克-斯科尔斯公式,每份认股权证的公允价值可计算为861.25丹麦克朗。
认股权证在授权日后三年到期,所有认股权证在授权日七周年时到期。新的权证是根据董事会于2021年2月23日通过的权证计划中规定的条款和条件授予的。有关Genmab认股权证计划的信息可在投资者>治理>薪酬>认股权证下找到。

About Genmab
Genmab is an international biotechnology company with a core purpose to improve the lives of people with cancer. For more than 20 years, Genmab's vision to transform cancer treatment has driven its passionate, innovative and collaborative teams to invent next-generation antibody technology platforms and leverage translational research and data sciences, fueling multiple differentiated cancer treatments that make an impact on people's lives. To develop and deliver novel therapies to patients, Genmab has formed 20+ strategic partnerships with biotechnology and pharmaceutical companies. Genmab's proprietary pipeline includes bispecific T-cell engagers, next-generation immune checkpoint modulators, effector function enhanced antibodies and antibody-drug conjugates.

关于Genmab
Genmab是一家国际生物技术公司,核心目标是改善癌症患者的生活。20多年来,Genmab改变癌症治疗的愿景推动其充满激情、创新和合作的团队发明下一代抗体技术平台,并利用转化研究和数据科学,推动多种差异化癌症治疗,对人们的生活产生影响。为了开发和向患者提供新的治疗方法,Genmab与生物技术和制药公司建立了20多个战略合作伙伴关系。Genmab的专利流水线包括双特异性T细胞调节器、下一代免疫检查点调节器、效应器功能增强型抗体和抗体-药物结合物。

Genmab is headquartered in Copenhagen, Denmark with locations in Utrecht, the Netherlands, Princeton, New Jersey, U.S. and Tokyo, Japan. For more information, please visit Genmab.com and follow us on Twitter.com/Genmab.

Genmab总部设在丹麦哥本哈根,在荷兰乌得勒支、美国新泽西州普林斯顿和日本东京设有办事处。欲了解更多信息,请访问Genmab.com,并在Twitter.com/genmab上关注我们。

Contact:        
Marisol Peron, Senior Vice President, Communications and Corporate Affairs
T: +1 609 524 0065; E: mmp@genmab.com

联系方式:
玛丽索尔·贝隆,高级副总裁,传播和公司事务
电话:+1 609 524 0065;电子邮件:mmp@genmab.com

Andrew Carlsen, Vice President, Head of Investor Relations
T: +45 3377 9558; E: acn@genmab.com
This Company Announcement contains forward looking statements. The words "believe", "expect", "anticipate", "intend" and "plan" and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with pre-clinical and clinical development of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products or technologies obsolete, and other factors. For a further discussion of these risks, please refer to the risk management sections in Genmab's most recent financial reports, which are available on and the risk factors included in Genmab's most recent Annual Report on Form 20-F and other filings with the U.S. Securities and Exchange Commission (SEC), which are available at www.sec.gov. Genmab does not undertake any obligation to update or revise forward looking statements in this Company Announcement nor to confirm such statements to reflect subsequent events or circumstances after the date made or in relation to actual results, unless required by law.
Genmab A/S and/or its subsidiaries own the following trademarks: Genmab®; the Y-shaped Genmab logo®; Genmab in combination with the Y-shaped Genmab logo®; HuMax®; DuoBody®; DuoBody in combination with the DuoBody logo®; HexaBody®; HexaBody in combination with the HexaBody logo®; DuoHexaBody® and HexElect®.

安德鲁·卡尔森,总裁副总裁,投资者关系主管
电话:+45 3377 9558;电子邮件:acn@genmab.com
本公司公告包含前瞻性陈述。“相信”、“期望”、“预期”、“打算”和“计划”等词语以及类似的表达方式识别前瞻性陈述。实际结果或业绩可能与此类陈述明示或暗示的任何未来结果或业绩大不相同。可能导致我们的实际结果或表现大相径庭的重要因素包括:与产品的临床前和临床开发相关的风险、与临床试验结果和进行相关的不确定性(包括不可预见的安全问题)、与产品制造相关的不确定性、市场对我们的产品缺乏认可度、我们无法管理增长、与我们的业务领域和市场相关的竞争环境、我们无法吸引和留住合适的合格人员、无法执行或缺乏执行能力。保护我们的专利和专有权利,我们与关联实体的关系,以及可能使我们的产品或技术陈旧等因素。有关这些风险的进一步讨论,请参阅Genmab最新财务报告中的风险管理部分,这些部分可在 Genmab中包含的危险因素最新年度报告:表格20-F 和其他文件 与美国证券交易委员会(美国证券交易委员会)合作,可在以下网址获得Www.sec.gov. Genmab不承担更新或修改本公司公告中的前瞻性陈述或确认此类陈述的任何义务以反映发生或发生日期后的后续事件或情况与实际结果有关的,除非法律另有要求。
Genmab A/S和/或其子公司拥有以下商标:®;Y形的Genmab标志®;Genmab与Y形Genmab标志相结合®;Humax®;多Body®;DuoBody与DuoBody标志相结合®;六元正文®; HexaBody与 HexaBody标志®;DuoHexaBody®六角选择®.

Company Announcement no. 50
CVR no. 2102 3884
LEI Code 529900MTJPDPE4MHJ122

公司公告第50号
注册表格编号2102 3884
雷码529900 MTJPDPE4MHJ122

Genmab A/S
Kalvebod Brygge 43
1560 Copenhagen V
Denmark

Genmab A/S
Kalvebod Brygge 43岁
1560哥本哈根五大
丹麦

Attachment

依附

  • 092022_CA50_Equity Grant
  • 092022_CA50_股权授予

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发